|
|
Substance Name: Protoveratrine B
RN: 124-97-0
UNII: AK816144R9
InChIKey: BFLXOMFFVWQPAZ-CEEVVQPDSA-N
Classification Codes
- Drug / Therapeutic Agent
- Natural Product
Molecular Formula
- C41-H63-N-O15
Molecular Weight
- 809.9407
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Protoveratrine B
Synonyms
- 4-21-00-06847 (Beilstein Handbook Reference)
- BRN 0077630
- EINECS 204-719-2
- Neoprotoveratrin
- Neoprotoveratrine
- NSC 7527
- Protoveratrine B
- UNII-AK816144R9
- Veratetrin
- Veratetrine
Systematic Names
- (3beta(2R,3R),4alpha,6alpha,7alpha,15alpha(R),16beta)-4,9-Epoxycevane-3,4,6,7,14,15,16,20-octol 6,7-diacetate 3-(2,3-dihydroxy-2-methylbutyrate) 15-(2-methylbutyrate)
- Cevane-3,4,6,7,14,15,16,20-octol, 4,9-epoxy-, 6,7-diacetate 3-(2,3-dihydroxy-2-methylbutanoate) 15-(2-methylbutanoate), (3beta(2R,3R),4alpha,6alpha,7alpha,15alpha(R),16beta)- (9CI)
- Cevane-3-beta,4-beta,6-alpha,7-alpha,14,15-alpha-16-beta,20-octol, 4,9-epoxy-, 6,7-diacetate 3-(threo-(+)-2,3-dihydroxy-2-methylbutyrate) 15-((-)-2-methylbutyrate)
- Cevane-3beta,4beta,6alpha,7alpha,14,15alpha,16beta,20-octol, 4,9-epoxy-, 6,7-diacetate 3-(threo-(+)-2,3-dihydroxy-2-methylbutyrate) 15-((-)-2-methylbutyrate) (8CI)
Registry Numbers
CAS Registry Number
- 124-97-0
FDA UNII
- AK816144R9
System Generated Number
- 0000124970
Structure Descriptors
InChI
1S/C41H63NO15/c1-10-19(3)34(47)56-33-28(46)27-23(17-42-16-18(2)11-12-25(42)38(27,9)50)24-15-39-32(40(24,33)51)30(54-22(6)45)29(53-21(5)44)31-36(39,7)14-13-26(41(31,52)57-39)55-35(48)37(8,49)20(4)43/h18-20,23-33,43,46,49-52H,10-17H2,1-9H3/t18-,19+,20+,23-,24-,25-,26-,27+,28+,29-,30+,31-,32+,33-,36-,37+,38+,39+,40-,41+/m0/s1InChIKey
BFLXOMFFVWQPAZ-CEEVVQPDSA-NSmiles
CC[C@@H](C)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LDLo | intravenous | 2025ug/kg (2.025mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Journal of Pharmacology and Experimental Therapeutics. Vol. 120, Pg. 412, 1957. |
mouse | LD50 | intravenous | 65ug/kg (0.065mg/kg) | Annales Pharmaceutiques Francaises. Vol. 14, Pg. 783, 1956. | |
mouse | LD50 | subcutaneous | 210ug/kg (0.21mg/kg) | LUNGS, THORAX, OR RESPIRATION: CYANOSIS BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: NAUSEA OR VOMITING | Journal of Pharmacology and Experimental Therapeutics. Vol. 113, Pg. 89, 1955. |
rabbit | LD50 | intravenous | 40ug/kg (0.04mg/kg) | Annales Pharmaceutiques Francaises. Vol. 14, Pg. 783, 1956. | |
rabbit | LD50 | subcutaneous | 170ug/kg (0.17mg/kg) | Annales Pharmaceutiques Francaises. Vol. 14, Pg. 783, 1956. | |
rat | LD50 | subcutaneous | 920ug/kg (0.92mg/kg) | Annales Pharmaceutiques Francaises. Vol. 14, Pg. 783, 1956. |